Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma

NCT ID: NCT01326390

Last Updated: 2016-07-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

13 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-05-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Impact on contrast dose or total volume of contrast required to effectively treat the targeted tumor.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney (Renal Cell) Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dTA/dBA C-arm fluoroscopy system with Dyna CT

C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry

Intervention Type DEVICE

DSA arteriogram- hepatic arteries

Standard of care

Intervention Type PROCEDURE

CO2 aortogram

Standard of care

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

X-ray image intensifier Siemens Angiography systems Angiography arteriography Aortography

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients must be affected by HCC
2. Patients must have diminished renal function (GFR\<60 ml/min/1.73m\^2)
3. Patients must be 18 years old or older
4. Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to the TACE procedure.
5. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

1. Subjects under the age of 18
2. Patients currently on dialysis
3. Pregnant women
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Stanford University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nishita N. Kothary

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stanford University School of Medicine

Stanford, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SU-07012010-6469

Identifier Type: OTHER

Identifier Source: secondary_id

HEP0035

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ga-68 Dolacga PET Scan in HCC Under RFA
NCT06792097 NOT_YET_RECRUITING